Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 10/20 | 0.78 |
| ▸ | MMP1 | P03956 | 9/20 | 0.78 |
| ▸ | MMP13 | P45452 | 9/20 | 0.78 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932299 | 0.98 | MMP9 (0.80) | MMP9MMP1MMP13ADAM17ALDH1A1 | |
| SCHEMBL7899148 | 0.89 | MMP9 (0.76) | MMP9MMP1MMP13ADAM17ALDH1A1 | |
| SCHEMBL7701550 | 0.88 | MMP9 (0.69) | MMP9MMP1MMP13ADAM17ALDH1A1 | |
| SCHEMBL6932325 | 0.87 | MMP9 (1.00) | MMP9MMP1MMP13ADAM17ALDH1A1 | |
| SCHEMBL6931438 | 0.87 | MMP9 (0.75) | MMP9MMP1MMP13ADAM17ALDH1A1 | |
| Hydroxyamine SCHEMBL7702805 | 0.85 | MMP9 (0.62) | MMP9MMP1MMP13ADAM17ALDH1A1 | |
| Hydroxyamine SCHEMBL7557247 | 0.84 | MMP13 (0.78) | MMP9MMP1MMP13ADAM17ALDH1A1 | |
| SCHEMBL6935134 | 0.83 | MMP9 (0.80) | MMP9MMP1MMP13ADAM17ALDH1A1 | |
| Hydroxyamine SCHEMBL7658069 | 0.83 | MMP9 (0.78) | MMP9MMP1MMP13ADAM17ALDH1A1 | |
| SCHEMBL6930534 | 0.82 | MMP9 (0.64) | MMP9MMP1MMP13ADAM17ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441023-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-03-14 | — | — | US | disclosed |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
| US-6197791-B1 | ANTIARTHRITIC AGENTS; WOUND HEALING AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP9 13/4885MMP1 4/4885MMP13 27/4885 |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP9 16/4885MMP1 7/4885MMP13 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.